William Lagarde
Pediatric Endocrinology · Raleigh, NCNPI 1811077837
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $975 of the $1,172 with a category attached, or 83.2%. It is spread thinly across 25 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $398 and has fallen 94.1% since, to $24 in 2025.
Across 56 payments — averaging $20.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tolmar, Inc.$174
- Novo Nordisk$138
- Ascendis Pharma Endocrinology Inc$100
- Dexcom, Inc.$83
- AbbVie$77
- Pfizer$67
- plus $533 from 19 others
Across 523 payments — averaging $203.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$78K
- Janssen Research & Development, LLC$26K
- Daiichi Sankyo Inc.$2K
- Boehringer Ingelheim France S.a.s.$618
What the payments were for
- Food & beverage$97583%
- Education$19717%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tolmar, Inc. | 12 | $174 |
| Novo Nordisk | 7 | $138 |
| Ascendis Pharma Endocrinology Inc | 3 | $100 |
| Dexcom, Inc. | 4 | $83 |
| AbbVie | 3 | $77 |
| Pfizer | 3 | $67 |
| Incyte Corporation | 1 | $56 |
| Tandem Diabetes Care, Inc. | 2 | $55 |
| IBSA Pharma Inc. | 2 | $45 |
| Sanofi-aventis U.S. LLC | 2 | $42 |
| Medtronic | 2 | $42 |
| Arbor Pharmaceuticals, Inc. | 2 | $32 |
| Endo Pharmaceuticals Inc. | 1 | $24 |
| Endo USA, Inc. | 1 | $24 |
| BETA Bionics, Inc. | 1 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Insulet Corporation | 1 | $23 |
| Azurity Pharmaceuticals, Inc. | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Sequel Med Tech, LLC | 1 | $21 |
| Abbott | 1 | $20 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Companion Medical, Inc. | 1 | $14 |
| Roche Diabetes Care, Inc. | 1 | $14 |
| AstraZeneca | 1 | $13 |
How this compares
$1,172 in reported general payments places this provider in the 60th percentile of 46 pediatric endocrinology providers in North Carolina.
See all pediatric endocrinology providers in North Carolina →
Other pediatric endocrinology in Raleigh
- Hillary LockemerRaleigh$18K
- Melissa CarlucciRaleigh$1K
- Mark HeninRaleigh$1K
- Janet LucienRaleigh$459
- Mark VanderwelCharlotte$42K
- Jennifer LawChapel Hill$40K
- Jakub MieszczakCharlotte$34K
- Nina JainSanford$22K
- Olga GuptaDurham$22K
- Michael StalveyWinston Salem$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.